Trial Profile
Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Planned end date changed from 1 Sep 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 23 Sep 2009 Official Title amended as reported by ClinicalTrials.gov.
- 23 Sep 2009 Planned end date changed from Aug 2009 to Sep 2010 as reported by ClinicalTrials.gov.